Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.

Journal

Nature medicine

ISSN: 1546-170X

Titre abrégé: Nat Med

Pays: United States

ID NLM: 9502015

Informations de publication

Date de publication:
12 Sep 2024

Historique:

received: 20 05 2024

accepted: 12 08 2024

medline: 13 9 2024

pubmed: 13 9 2024

entrez: 12 9 2024

Statut: aheadofprint

Résumé

Human immunodeficiency virus type 1 (HIV-1)-specific broadly neutralizing monoclonal antibodies (bNAbs) have to date shown transient viral suppression when administered as monotherapy or as a cocktail of two antibodies

Identifiants

DOI: 10.1038/s41591-024-03247-5 PMID: 39266747

pubmed: 39266747

doi: 10.1038/s41591-024-03247-5

pii: 10.1038/s41591-024-03247-5

doi:

Banques de données

ClinicalTrials.gov

['NCT03721510']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Subventions

Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)

ID : AI124377, AI128751, AI145801, AI149670, AI164556, AI169615, AI177687

Informations de copyright

Références

Stephenson, K. E. et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat. Med. 27, 1718–1724 (2021).

doi: 10.1038/s41591-021-01509-0 pubmed: 34621054 pmcid: 8516645

Bar-On, Y. et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat. Med. 24, 1701–1707 (2018).

doi: 10.1038/s41591-018-0186-4 pubmed: 30258217 pmcid: 6221973

Gaebler, C. et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature 606, 368–374 (2022).

doi: 10.1038/s41586-022-04597-1 pubmed: 35418681 pmcid: 9177424

Sneller, M. C. et al. Combination anti-HIV antibodies provide sustained virological suppression. Nature 606, 375–381 (2022).

doi: 10.1038/s41586-022-04797-9 pubmed: 35650437 pmcid: 11059968

Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat. Med. 28, 1288–1296 (2022).

doi: 10.1038/s41591-022-01815-1 pubmed: 35551291 pmcid: 9205771

Wagh, K. et al. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade C infection. PLoS Pathog. 12, e1005520 (2016).

doi: 10.1371/journal.ppat.1005520 pubmed: 27028935 pmcid: 4814126

Stephenson, K. E., Wagh, K., Korber, B. & Barouch, D. H. Vaccines and broadly neutralizing antibodies for HIV-1 prevention. Annu. Rev. Immunol. 38, 673–703 (2020).

doi: 10.1146/annurev-immunol-080219-023629 pubmed: 32340576 pmcid: 7375352

Lynch, R. M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).

doi: 10.1126/scitranslmed.aad5752 pubmed: 26702094

Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185–191 (2017).

doi: 10.1038/nm.4268 pubmed: 28092665 pmcid: 5467219

Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487–491 (2015).

doi: 10.1038/nature14411 pubmed: 25855300 pmcid: 4890714

Crowell, T. A. et al. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV 6, e297–e306 (2019).

doi: 10.1016/S2352-3018(19)30053-0 pubmed: 31000477 pmcid: 6693657

Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479–484 (2018).

doi: 10.1038/s41586-018-0531-2 pubmed: 30258136 pmcid: 6166473

Gunst, J. D. et al. Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. Nat. Med. 29, 2547–2558 (2023).

doi: 10.1038/s41591-023-02547-6 pubmed: 37696935 pmcid: 10579101

Julg, B. & Barouch, D. Broadly neutralizing antibodies for HIV-1 prevention and therapy. Semin. Immunol. 51, 101475 (2021).

doi: 10.1016/j.smim.2021.101475 pubmed: 33858765

Wang, C. et al. Landscape of human immunodeficiency virus neutralization susceptibilities across tissue reservoirs. Clin. Infect. Dis. 75, 1342–1350 (2022).

doi: 10.1093/cid/ciac164 pubmed: 35234862 pmcid: 9555844

Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021).

doi: 10.1056/NEJMoa2031738 pubmed: 33730454 pmcid: 8189692

Bricault, C. A. et al. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 25, 59–72 e58 (2019).

doi: 10.1016/j.chom.2018.12.001 pubmed: 30629920 pmcid: 6331341

Sok, D. et al. A prominent site of antibody vulnerability on HIV envelope incorporates a motif associated with CCR5 binding and its camouflaging glycans. Immunity 45, 31–45 (2016).

doi: 10.1016/j.immuni.2016.06.026 pubmed: 27438765 pmcid: 4990068

de Taeye, S. W. et al. Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers. J. Biol. Chem. 294, 5616–5631 (2019).

doi: 10.1074/jbc.RA118.005396 pubmed: 30728245 pmcid: 6462529

Borducchi, E. N. et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563, 360–364 (2018).

doi: 10.1038/s41586-018-0600-6 pubmed: 30283138 pmcid: 6237629

Walker-Sperling, V. E. K. et al. Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques. Nat. Commun. 13, 3463 (2022).

doi: 10.1038/s41467-022-31196-5 pubmed: 35710819 pmcid: 9203527

Dashti, A. et al. AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques. Nat. Med. 29, 2535–2546 (2023).

doi: 10.1038/s41591-023-02570-7 pubmed: 37783968 pmcid: 10579098

Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559–563 (2017).

doi: 10.1038/nature21435 pubmed: 28289286 pmcid: 5458531

Zalevsky, J. et al. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157–159 (2010).

doi: 10.1038/nbt.1601 pubmed: 20081867 pmcid: 2855492

Mahomed, S. et al. Safety and pharmacokinetics of monoclonal antibodies VRC07-523LS and PGT121 administered subcutaneously for human immunodeficiency virus prevention. J. Infect. Dis. 226, 510–520 (2022).

doi: 10.1093/infdis/jiac041 pubmed: 35134995 pmcid: 9417124

Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 105, 7552–7557 (2008).

doi: 10.1073/pnas.0802203105 pubmed: 18490657 pmcid: 2387184

Seaman, M. S. et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439–1452 (2010).

doi: 10.1128/JVI.02108-09 pubmed: 19939925

Montefiori, D. C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. Chapter 12, 12.11.1–12.11.17 (2005).

Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108–10125 (2005).

doi: 10.1128/JVI.79.16.10108-10125.2005 pubmed: 16051804 pmcid: 1182643

Li, M. et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80, 11776–11790 (2006).

doi: 10.1128/JVI.01730-06 pubmed: 16971434 pmcid: 1642599

Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature 566, 120–125 (2019).

doi: 10.1038/s41586-019-0898-8 pubmed: 30700913 pmcid: 6447073

Siepel, A. C., Halpern, A. L., Macken, C. & Korber, B. T. A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res. Hum. Retroviruses 11, 1413–1416 (1995).

doi: 10.1089/aid.1995.11.1413 pubmed: 8573400

Bricault, C. A. et al. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 25, 59–72.e8 (2019).

doi: 10.1016/j.chom.2018.12.001 pubmed: 30629920 pmcid: 6331341

Guindon, S. et al. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst. Biol. 59, 307–321 (2010).

doi: 10.1093/sysbio/syq010 pubmed: 20525638

Yant, L. J. et al. The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J. Virol. 80, 5074–5077 (2006).

doi: 10.1128/JVI.80.10.5074-5077.2006 pubmed: 16641299 pmcid: 1472056

Barouch, D. H. et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482, 89–93 (2012).

doi: 10.1038/nature10766 pubmed: 22217938 pmcid: 3271177

Borducchi, E. N. et al. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature 540, 284–287 (2016).

doi: 10.1038/nature20583 pubmed: 27841870 pmcid: 5145754

Bashirova, A. A. et al. HLA tapasin independence: broader peptide repertoire and HIV control. Proc. Natl Acad. Sci. USA 117, 28232–28238 (2020).

doi: 10.1073/pnas.2013554117 pubmed: 33097667 pmcid: 7668082